Magnetar Financial LLC Makes New Investment in Pfizer Inc. $PFE

Key Points

• Magnetar Financial LLC acquired a new position in Pfizer Inc. by purchasing 71,927 shares worth approximately $1.82 million, as disclosed in their recent 13F filing with the SEC.
• Pfizer's stock has a current market price of $24.74, reflecting a modest increase of 0.6% and is trading well below its 12-month high of $30.43.
• The company recently announced a quarterly dividend of $0.43 per share, equating to an annualized yield of 7.0%, with a payout ratio of 91.49%.

Magnetar Financial LLC bought a new position in shares of Pfizer Inc. (NYSE:PFE - Free Report) in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 71,927 shares of the biopharmaceutical company's stock, valued at approximately $1,823,000.

A number of other institutional investors also recently modified their holdings of the business. Clarity Asset Management Inc. bought a new stake in Pfizer during the 4th quarter valued at $27,000. Gould Capital LLC grew its position in shares of Pfizer by 97.2% in the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 493 shares in the last quarter. GKV Capital Management Co. Inc. bought a new stake in shares of Pfizer during the 1st quarter valued at $27,000. North Capital Inc. purchased a new stake in Pfizer during the 1st quarter worth about $28,000. Finally, Bayforest Capital Ltd purchased a new position in Pfizer during the 1st quarter valued at about $28,000. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Price Performance

NYSE PFE traded up $0.14 on Friday, reaching $24.74. 37,002,549 shares of the company's stock traded hands, compared to its average volume of 42,996,172. The stock has a market cap of $140.65 billion, a PE ratio of 13.16, a P/E/G ratio of 0.88 and a beta of 0.55. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $30.43. The stock has a 50-day simple moving average of $24.79 and a 200 day simple moving average of $24.37. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.58 by $0.20. The company had revenue of $14.65 billion during the quarter, compared to analysts' expectations of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The firm's revenue was up 10.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 2nd. Investors of record on Friday, July 25th will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.0%. The ex-dividend date is Friday, July 25th. Pfizer's dividend payout ratio is currently 91.49%.

Analyst Ratings Changes

PFE has been the subject of a number of analyst reports. HSBC cut their price objective on shares of Pfizer from $27.00 to $26.00 and set a "buy" rating for the company in a research report on Monday, May 19th. Jefferies Financial Group raised their price target on shares of Pfizer from $32.00 to $33.00 and gave the company a "buy" rating in a report on Wednesday, May 21st. Citigroup increased their price objective on Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a research report on Wednesday, August 6th. Morgan Stanley boosted their target price on Pfizer from $32.00 to $33.00 and gave the stock an "equal weight" rating in a research report on Wednesday, August 6th. Finally, Berenberg Bank decreased their target price on Pfizer from $28.00 to $25.00 and set a "hold" rating on the stock in a research note on Thursday, May 29th. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus target price of $28.12.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.